



Centrum pro výzkum  
toxických látek  
v prostředí

# BIOMARKERS AND TOXICITY MECHANISMS

## 09 – Mechanisms Nuclear Receptors

Luděk Bláha, PŘF MU, RECETOX  
[www.recetox.cz](http://www.recetox.cz)


Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.





INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

# Various signalling types ... now focus on nuclear receptors



## Polypeptides



## Amino Acid Derivatives



## Steroids



Not lipid soluble;  
bind to receptors on  
surface of target cell

Most not lipid soluble;  
bind to receptors on  
surface of target cell

Lipid soluble;  
often bind to  
receptors inside  
target cell

# NUCLEAR (Intracellular) RECEPTORS in summary

- Important physiological functions, and
- Important roles in pathologies and chemical toxicity
  - Endocrine disruption
  - Dioxin-like toxicity, etc.
- All NRs share similar structure and mechanisms of action
  - Act as direct transcription factors on DNA
- Natural ligands are small lipophilic hormones (steroids, thyroids, retinoids)
  - Role in toxicity – NR are modulated (activated/inhibited) by structurally close xenobiotics



# Natural ligands of NR

- **Small, lipid-soluble molecules**

- Diffuse through plasma and nuclear membranes and interact directly with the transcription factors they control.

- **STEROID HORMONES:**


- sex steroids (estrogen, progesterone, testosterone)
- corticosteroids (glucocorticoids and mineralcorticoids)

- **OTHER HORMONES and ligands**


Thyroid hormone, vitamin D3, retinoic acid, ligands of AhR

- **Small molecules - gases**


e.g. NO (signaling for immune reactions)



**Cortisol**




**Retinoic acid**



**Thyroxine**






## Fate and action of **HORMONES** activating NRs

- Circulation in the blood bound to transport proteins
  - Dissociation from carrier at target cells
  - Passing through cell membrane
  - Binding to an intracellular receptor (either in the cytoplasm or the nucleus)
  - Hormone-receptor complex binds to hormone responsive elements in DNA
    - Regulation of gene expression
- De-regulation at any level described above = TOXICITY


# NR signalling is complex ... examples of complexity (1)

1. Receptor activation is dependent not only on „ligand“ (**glucocorticoid**) but also on „inhibitor“ protein (**HSPs**)
2. Dimerization (after the activation) is often needed for proper action (binding to **GREs** – *glucocorticoid responsive elements*)
3. Receptor with ligand can activate its own targets (GREs) as well as „repress“ other binding sites (**TFREs**)




# NR signalling is complex ... examples of complexity 2

4. „**Co-activator**“ proteins are needed for proper action on DNA



5. Nuclear receptor action are (also) controlled - stimulated / suppressed - by **other signalling pathways** (e.g. **phosphorylation by protein kinases**)






# NR signalling is complex ... examples of complexity 3

## 6. Interaction (crosstalk) among various NRs

- “antiestrogenicity” of AhR ligands
- fast clearance of retinoids after AhR activation
- Immunosuppressions after ER activations



# Details - specificities of NRs

- Regulation of transcription activity - mechanisms may vary
  - Steroid receptors often **dimerize** with a partner to activate gene transcription
  - Receptors for vitamin D, retinoic acid and thyroid hormone form **heterodimers** and then bind to responsive elements on DNA
    - Second component of the heterodimer is RXR monomer (i.e, RXR-RAR; RXR-VDR)
- **NR dimers**
  - Heterodimeric receptors - exclusively nuclear;
    - without ligand represses transcription (by binding to their cognate sites in DNA)
  - Homodimeric receptors
    - mostly cytoplasmic without ligands → hormone binding leads to nuclear translocation of receptors

# STEROIDS - most studied ligands detailed view




# Steroid hormones - a review

Steroid hormones are derived from cholesterol metabolism in mitochondria


## Cortisol

The dominant glucocorticoid in humans. Synthesized from progesterone in the *zona fasciculata* of the adrenal cortex. Involved in stress adaptation, elevates blood pressure and  $\text{Na}^+$  uptake. Immunomodulation.




## Aldosterone

Principal mineralocorticoid. Produced from progesterone in the *zona glomerulosa* of adrenal cortex, raises blood pressure and fluid volume, increases  $\text{Na}^+$  uptake.




## Estradiol

An estrogen, principal female sex hormone, produced in the ovary, responsible for secondary female sex characteristics. After menopause estrogen is produced from testosterone in the adrenal glands.




## Progesterone

Produced from pregnenolone and secreted from the corpus luteum. Responsible for changes associated with luteal phase of the menstrual cycle, differentiation factor for mammary glands




## Testosterone

An androgen, male sex hormone synthesized in the testes from progesterone. Responsible for secondary male sex characteristics.




## Pregnenolone

Made directly from cholesterol, the precursor molecule for all  $\text{C}_{18}$ ,  $\text{C}_{19}$  and  $\text{C}_{21}$  steroids



# STEROID HORMONE biosynthesis



Why are NR important?

→ **common mediators  
of Endocrine Disruption**





# Endocrine disruption



- **Interference of xenobiotics with normal functioning of hormonal system**

## Known consequences


- Disruption of homeostasis, reproduction, development, and/or behavior (and other hormone-controlled processes), such as
- Shift in sex ratio, defective sexual development
  - Low fecundity/fertility
  - Hypo-immunity, carcinogenesis
  - Malformations
  - etc.







# Toxicants interact with hormonal system at different levels



## Consequences (both negative!)

Suppression



Stimulation

### Possible mechanisms of endocrine disruption

- Disruption of the „master“ hormones (FSH/LH)
- Decrease of HR cellular levels
- Nonphysiological activation of hormone receptor (HR)
- Binding to HR without activation
- Changes in hormone metabolism (clearance)

**Mechanisms  
of toxicant effects  
in detail**

→ various MoAs  
of endocrine disruption

biosynthesis and release of hormones

e.g. steroidogenesis

e.g. modulation of CYP11A and/or CYP19 activities

binding to plasmatic transport proteins

e.g. down-regulation of receptor levels

binding to nuclear hormonal receptor (HR)

Direct interference (activation / inhibition)

activation of HR

(dissociation of associated heat shock proteins, formation of homodimers)

e.g. modulation of other nuclear receptors  
(PPAR/RXR, RXR/TR)

binding of the activated receptor complex to specific DNA motifs - HREs

chromatin rearrangement and transcription of estrogen-inducible genes


effects at the cellular, tissue, organ, organism, and/or population level




# Examples – modulations of (synthetic) enzyme activities

Phytoestrogens promote **synthesis of estrogens**  
→ feminization

Conversion of circulating steroid precursors into oestrogens in human breast carcinoma tissue




Crosstalk with other signalling pathways (such as **cAMP**), which can be target to toxicants




# ESTROGEN RECEPTOR – ER


the most studied target of EDCs



# Estrogens



17-β-estradiol



estriol




- **Synthesis in ovaries**
- **Functions**
  - key roles in female hormone regulation and signalling
  - responsible for metabolic, behavioural and morphologic changes occurring during stages of reproduction
  - involved in the growth, development and homeostasis in a number of tissues
  - control the bone formation, regulation of homeostasis, cardiovascular system and behaviour
  - regulate **production, transport and concentration of testicular liquid and anabolic activity of androgens** in males
- **DISRUPTION OF ESTROGEN SIGNALLING**  
→ many documented effects in aquatic biota & laboratory organisms



Kidd, K.A. et al. 2007. Collapse of a fish population following exposure to a synthetic estrogen. *Proceedings of the National Academy of Sciences* 104(21):8897-8901



5 ng/L (!)  
7 years




# ESTROGEN RECEPTORS - subtypes

ER- $\alpha$  (in breast, ovary, brain, liver, bone and cardiovascular system, adrenals, testis and urogenital tract)

ER- $\beta$  (in kidneys, prostate and gastrointestinal tract)

(ER- $\gamma$  in fish)



# Environmental estrogens (xenoestrogens, exoestrogens)

- >> Highly diverse group of substances
- >> Do not necessarily share structural similarity to the prototypical estrogen 17 $\beta$ -estradiol
- >> may act as **AGONISTS** and/or **ANTAGONISTS** (depending on situation and concentration!)


## Natural products

### genistein

naringenin

coumestrol

zearalenone



## Various POPs

DDT

kepone

PCBs/OH-PCBs

PAHs and dioxins




## Industrial chemicals

### Bisphenol A

Nonionic surfactants

Pthalate esters (eg. DEHP)

Endosulfan (pesticide)



## Pharmaceuticals

Ethinyl estradiol

Diethylstilbestrol

gestodene

norgestrel





# Exoestrogens - Relative Potencies to bind to ER $\alpha$ (REPs)

REP – a measure of toxic potency of a compound (similar also at other NRs)

| Chemical group      | Substance                              | REP                 |
|---------------------|--|---------------------|
| Endogenous hormones | Estradiol                              | 1                   |
|                     | Estriol                                | $6,3 \cdot 10^{-3}$ |
|                     | Testosteron                            | $9,6 \cdot 10^{-6}$ |
| Phytoestrogens      | Cuomestrol                             | $6,8 \cdot 10^{-3}$ |
|                     | Genistein                              | $4,9 \cdot 10^{-4}$ |
| Pesticides          | o,p'-DDT                               | $1,1 \cdot 10^{-6}$ |
| PCBs                | 2,4,6-trichlorobiphenyl-4'-ol          | $1 \cdot 10^{-2}$   |
|                     | 2,5-dichlorobiphenyl-4'-ol             | $6,2 \cdot 10^{-3}$ |
|                     | 3,3',5,5'tetrachlorobiphenyl-4,4'-diol | $1,6 \cdot 10^{-4}$ |
| alkylphenoles       | 4-tert-oktylphenol                     | $3,6 \cdot 10^{-6}$ |
| phthalates          | butylbenzylphthalate                   | $4 \cdot 10^{-6}$   |

REP (Relative Potencies) of selected compounds related to 17- $\beta$ -estradiol derived from reporter yeast assay

# How to assess for ESTROGENICITY?

## number of in vivo and in vitro methods available

| Assay (ref.)                                       | Exposure type  | Detects ER-dependent agents? | Detects non-ER-dependent agents? | Distinguishes agonist versus antagonist? | Pharmacokinetic and metabolism included? |
|--|----------------|------------------------------|----------------------------------|--|--|
| <b>Receptor-based assays</b>                       |                |                              |                                  |  |  |
| Receptor binding assay (27)                        | Cell lysate    | Yes                          | No                               | No                                       | No                                       |
| Receptor activation assay (32-34)                  | Cells in vitro | Yes                          | No                               | Yes <sup>a</sup>                         | No                                       |
| <b>In vitro estrogen-regulated response assays</b> |                |                              |                                  |  |  |
| MCF-7 cell proliferation assay (41)                | Cells in vitro | Yes                          | Limited                          | Yes <sup>a</sup>                         | No                                       |
| Induction assays (46,48)                           | Cells in vitro | Yes                          | Limited                          | Yes <sup>a</sup>                         | No                                       |
| DNA synthesis assays (47)                          | Cells in vitro | Yes                          | Limited                          | Yes <sup>a</sup>                         | No                                       |
| <b>In vivo estrogen-regulated response assays</b>  |                |                              |                                  |  |  |
| Uterotrophic response assay (49)                   | Whole animal   | Yes                          | Limited                          | Yes <sup>a</sup>                         | Yes                                      |
| Vaginal cornification assay (50)                   | Whole animal   | Yes                          | Limited                          | Yes <sup>a</sup>                         | Yes                                      |
| Vaginal opening (11)                               | Whole animal   | Yes                          | Limited                          | Yes <sup>a</sup>                         | Yes                                      |
| Uterine fluid imbibition (11)                      | Whole animal   | Yes                          | Limited                          | Yes <sup>a</sup>                         | Yes                                      |
| Uterine epithelial hypertrophy (51)                | Whole animal   | Yes                          | Limited                          | Yes <sup>a</sup>                         | Yes                                      |
| <b>Inhibition of steroid synthesis assays</b>      |                |                              |                                  |  |  |
| In vitro ovarian steroid assay (55)                | Minced tissue  | No                           | Yes                              | Yes                                      | No                                       |
| Ex vivo ovarian steroid assay (56)                 | Whole animal   | No                           | Yes                              | Yes                                      | Yes                                      |

<sup>a</sup>Detection of antagonists requires use of additional groups with test material + estradiol.

Janošek, J., Hilscherová, K., Bláha, L., and Holoubek, I. (2006). Environmental xenobiotics and nuclear receptors-Interactions, effects and in vitro assessment. *Toxicology in Vitro* 20, 18-37.



# In vitro assays for estrogenicity


- **Level 1 – interaction of toxicant with the protein (receptor)**

- **INTERACTION (BINDING) to the receptor**

- competitive ligand binding assays

- Various variants (e.g. displacement of radioactive substrate, fluorescence resonance energy transfer (*FRET*) techniques etc.

→ information only about “binding potency” but the effect remains unknown (? Activation / suppression / no effect ?)




# In vitro assays for estrogenicity

- **Level 2 - effects at cellular level**

- interference with receptor biological activity

- **Cell proliferation assays**

- Estrogens induce proliferation





# In vitro assays for estrogenicity

- **Level 2 - effects at cellular level**
  - interference with receptor biological activity
- **Endogenous protein expression** (or enzyme activity) assays
  - Often **reporter gene assays**

## Cell assays *in vitro*


- Cells (e.g. breast carcinoma) naturally carrying functional ER.
- Genetic modification - stable transfection with firefly **luciferase gene**: under the control of ER
- Estrogens in media → light induction




# Luciferase reporter assay for estrogenicity in brief

96 microwell plate  
cultivation of transgenic cell lines

ER: breast carcinoma **MVLN cells**



Exposure (6 – 24 h)  
standards / samples



## Similar principle for other NRs activities



### Mammalian cells

- \* AhR – H4IIE.luc cells (CALUX)
- \* AR – MDA.kb2 cells
- \* RAR/RXR - P19/A15 cells


### Yeast models

- \* Luciferase based
- \* Also beta-galactosidase etc.


Cell lysis  
→ extraction of induced luciferase



Luminescence determination  
(microplate luminescence reader)



# Bioassay (biosensor) for NR-modulator based on yeast cells



## IN VIVO ASSAYS FOR ESTROGENICITY

- uterotropic assay
- vaginal cornification assay

Rat uterus  
Control



Estrogen exposure




- production of estrogen-inducible proteins  
(e.g. **vitellogenin** and zona radiata protein)  
→ also discussed at “biomarkers” part
- standard (in vivo) test procedures for reproductive and developmental toxicity
  - using mice, rats, fish, amphibians etc.



# ANDROGEN RECEPTOR (AR)


*role in toxicity confirmed ... but less explored than ER*

Androgen receptor DNA binding domain.



# Androgens

- **Role in males similar to the of estrogens in females**
  - development of male sexual characteristics
  - stimulating protein synthesis, growth of bones
  - cell differentiation, spermatogenesis
  - male type of behaviour



# Androgens

- Endogenous ligands – androgen hormones

- Two key androgens

- testosterone (T)

- dihydrotestosterone (DHT)

- Other androgens – androstanediol, dehydroepiandrosterone, androstenedione


- **T:** synthesis in testis (Leydig cells)

- in lesser extent in adrenals


- **DHT:** Formed **extratesticular** from T

- In several tissues (seminal vesicles, prostate, skin) higher affinity to androgen receptor than T

- Daily production 5-10% of testosterone



Testosterone




Dihydrotestosterone



# Mechanisms of androgen signalling disruption

## 1) Binding to AR

- Mostly competitive inhibition
- xenobiotics mostly DO NOT activate AR-dependent transcription
- Only few compounds able to activate AR in the absence of androgen hormones but they are **anti-androgenic in the presence of strong androgens like T or DHT**
  - metabolites of **fungicide vinclozoline**, some PAHs




## 2) FSH/LH (gonadotropins) signalling disruption – less explored

- FSH/LH expression - regulation via negative feedback by testosterone
- Suppression → alterations of spermatogenesis

# Mechanisms of androgen signalling disruption

## 3) Alterations of testosterone synthesis

- Inhibition of P450<sub>scc</sub> needed for side chain cleavage of cholesterol or inhibitions of 17-beta-hydroxylase and other CYPs
  - fungicide **ketoconazol**



## 4) Testosterone metabolic clearance

- Induction of detoxification enzymes (UDP-glucuronosyltransferase or monooxygenases CYP1A, 1B)
  - Pesticides endosulfan, mirex, o-p'-DDT




# Effects of male exposure to antiandrogens

- **Exposure during prenatal development:**
  - malformations of the reproductive tract
    - reduced anogenital distance
    - **hypospadias** (abnormal position of the urethral opening on the penis)
    - vagina development
    - undescendent ectopic testes
    - atrophy of seminal vesicles and prostate gland
- **Exposure in prepubertal age:**
  - delayed puberty
  - reduced seminal vesicles
  - reduced prostate
- **Exposure in adult age:**
  - oligospermia
  - azoospermia
  - loss of sexual libido

Search google for  
illustrations

## Antiandrogenic compound

- tris-(4-chlorophenyl)-methanol
  - Ubiquitous contaminant of uncertain origin
  - Probable metabolite of DDT-mixture
  - Levels in human blood serum cca. 50nM
  - antiAR potency - EC50 – cca. 200nM



AR-binding – potencies - reference **DHT: EC50 ~ 0.1  $\mu$ M)**


| Compound                                     | IC <sub>50</sub> ( $\mu$ M)        |
|--|------------------------------------|
| Benz[a]anthracene                            | 3.2                                |
| Benzo[a]pyrene                               | 3.9                                |
| Dimethylbenz[a]anthracene                    | 10.4                               |
| Chrysene                                     | 10.3                               |
| Dibenzo[a,h]anthracene                       | activation in range 0.1-10 $\mu$ M |
| Bisphenol A                                  | 5                                  |
| vinclozolin metabolites                      | 9.7                                |
| hydroxyflutamide                             | 5                                  |
| Aroclor typical values                       | 0.25-1.11                          |
| Individual PCBs typical values               | 64 - 87                            |
| <b><i>tris</i>-(4-chlorophenyl)-methanol</b> | <b>0.2</b>                         |



# (Anti)androgenicity assessment

- **In vivo Hershberger assay**
  - castrated rats treated with examined substance
  - Endpoint – after 4-7 days – seminal vesicles and ventral prostate weight
- **In vivo measurement of testosterone blood levels**
- **In vitro cell proliferation assays**
  - cells with androgen-dependent growth: mammary carcinoma cell lines
  - prostatic carcinoma cell lines
- **Receptor-reporter assays**
  - Gene for luciferase (or GFP) under control of AR
    - AR-CALUX (human breast carcinoma T47D)
    - PALM (human prostatic carcinoma PC-3)
    - CHO515 (Chinese hamster ovary CHO)
  - Yeast transfected cells
    - beta-galactosidase reporter

# THYROID SIGNALLING



# Thyroid hormones

- Crucial roles in metabolism, development and maturation
  - Regulation of metabolism
    - increasing oxygen consumption
    - modulating levels of other hormones (insulin, glucagon, somatotropin, adrenalin)
  - Important in cell differentiation
  - Crucial role in development of CNS, gonads and bones
- EDC compounds interfering with thyroid signalling  
**“GOITROGENS”**
- Many food (vegetables) contain goitrogens



HYPOTHYROIDISM



HYPERTHYROIDISM

Foods to Avoid/Reduce for Optimal Thyroid Health

**Goitrogenic Foods**

Foods rich in sulfur are generally goitrogenic.


| Vegetables        |                 | Fruits              | Seeds               |
|-------------------|-----------------|---------------------|---------------------|
| Arugula           | Kohlrabi        | Figs*               | Flaxseeds*          |
| Broccoli*         | Leeks           | Grapes              | Hemp                |
| Brussels Sprouts* | Mustard Greens* | Peaches             | Millet*             |
| Cabbage*          | Okra            | Pears               | Pumpkin Seeds       |
| Cassava Root      | Radish*         | Plums               | <b>Beans/Grains</b> |
| Cauliflower*      | Spinach         | Strawberries        | Garbanzo Beans*     |
| Collard Greens*   | Squash          | <b>Nuts</b>         | Soy Beans*          |
| Eggplant          | Sweet Potato    | Almonds*/Cashews    | Wheat*/Kamut        |
| Horseradish       | Tomato          | Peanuts*/Pine Nuts* | Barley*/Spelt       |
| Kale*             | Turnips*        | Walnuts             | Bulgur/Rye*         |

JeevaLifestyle.com \* high on goitrogen

# Thyroid hormones

## Thyroxine (T4)


Also called tetraiodothyronine  
Contains 4 iodide ions



Thyroxine (T<sub>4</sub>)

## Triiodothyronine (T3)

Contains 3 iodide ions  
-Most T3 produced  
by deiodination  
in target tissues (deiodinases)





3,5,3'-Triiodothyronine (T<sub>3</sub>)

T4 – prohormone  
5 -deiodination → active form, T3

# Enzymes involved in Thyroid hormone metabolism


- **Thyroid peroxidases**
  - iodination of tyrosyl residues
  - coupling of iodinated tyrosyl residues
- **Thyroid deiodinases**
  - D1, D2 - activation of T4 into T3 via deiodination on „outer“ ring
  - D3 - deactivation into rT3 via deiodination on „inner“ ring
- **Many goitrogens** affect expression, activities and outcomes of these key enzymes
  - **PTU – propylthiouracil**  
→effect deiodinases
  - **Thiocyanate ([SCN]<sup>-</sup>) or perchlorate (NaClO<sub>4</sub>)**  
→effect on iodine uptake




# Transport of thyroid hormones in blood

- SPECIFIC TRANSPORTERS in blood
  - regulating free T4 and T3 levels
  - 3 types :
    - Thyroid-binding prealbumin (transthyretin) (20-25%)
    - Albumin (5-10%)
    - Thyroid binding globulin (**TBP**, 75%)
- **NUMBER OF EDCs** → act on transport proteins
  - OH-PCBs, brominated and chlorinated flame retardants, DDT, dieldrin
  - OH-PCBs – equal affinity to **TBP** as T4 and T3 (!!!)
- Increased levels of “free T4” in blood
  - negative feedback to TSH release
    - increased depletion
    - increased weight, histological changes in thyroid gland
  - Documented after exposures to POPs in mammals, birds, fish

Hydroxylated PCB formation



Polybrominated diphenyl ethers (PBDEs) – flame retardants



## Other mechanisms of goitrogens' toxicity

- **Competitive binding to TR**
  - Probably less important than binding to TBP
    - Chemicals that affect thyroid signalling in vivo mostly don't bind to TR (DDT, PCBs) or bind with much lesser affinity than T3 (OH-PCBs – 10000x)
- **Accelerated depletion of hormones**
  - UDP-glucuronosyltransferase – detoxification enzyme (II.biotransformation phase)
  - Induced by PCBs and dioxins  
→ indirect goitrogens




# Effects of thyroid disruption

- **Exposures during prenatal stages**

- severe damage of CNS (cretinism, delayed eye opening, cognition)
- Megalotestis
- Histological changes in thyroid gland (goitre)

- **Exposures during development**

- nervous system fails to develop normally
- mental retardation
- skeletal development





# Assessment of goitrogen effects

(For information only)

- **In vivo approaches**

- TH serum levels – simple, nondestructive x variation within time of day, age, sensitive to other than biochemical stresses
- Thyroid gland weight and follicular cells number
- Developmental toxicity assays - delayed eye opening, abnormalities in brain development and cognition, increased testis weight and sperm counts
- Perchlorate discharge test (TH synthesis)
- Hepatic UDP-glucuronosyltransferase activity (marker of enhanced TH clearance from serum)


- **In vitro**

- Enzyme inhibition assays (thyroid peroxidase, deiodinases) – assessment of thyroid metabolism
- Competitive binding assays with TBP
- TH- dependent proliferation assay (pituitary tumor GH3, thyroid tumors like FRTL-5 cell line) or TSH-dependent proliferation assay (thyroid tumors)
- Receptor-reporter gene assays with luciferase (monkey kidney CV-1, chinese hamster ovary CHO or insect Sf9 cell lines)



# Vitamin A and its derivatives RETINOIDS

(role in toxicity - still in the research phase)




# RETINOIDS

Sources: from diet - **dietary hormones**


Retinyl esters – animal sources

Plant carotenoids


$\beta$ -karoten



Retinol (vitamin A)



Retinoic Acid



## Retinoids and their functions

- Regulation of development and homeostasis in tissues of vertebrates and invertebrates
- Development of embryonic, epithelial cells (gastrointestinal tract, skin, bones)
- Necessary for vision
- Suppressive effects in cancer development
- Important for cell growth, apoptosis and differentiation
- Antioxidative agent
- Affect nervous and immune function




# Retinoid transport

RE: Retinol-Ester


R: Retinol

RBP: Retinol Binding Protein (LMW)

TTR: Transthyrethin (HMW)



# Retinoid fate in the cells




## Retinoid binding proteins

- CRBP – cellular retinol binding protein
  - binding of retinol, immediate decrease of retinol concentration
- CRBAP – cellular retinoic acid binding protein
  - Controlling the ratio free retinol/free retinoic acid

# RAR/RXR and RA

- Isoforms of RAR a RXR
  - Formation of homo- and heterodimers
  - 48 possible RAR-RXR heterodimers
  - sensitive regulation of gene expression
- RXR – heterodimers with other receptors
  - VDR, TR, PPAR ... → see crosstalk
- **RETINOIC ACID (RA)**
- 3 basic subtypes
  - all-trans- (ATRA)
  - 9-cis- and 13-cis-retinoic acid
- All-trans RA (ATRA) binds selectively to RAR
- Cis RA bind to both receptor types



# Disruption of retinoid signalling by xenobiotics

- **Possible modes of action – disruption of retinoid signalling:**
  - **Metabolization** of retinoids by detoxication enzymes
  - Disruption of binding retinoids **to transport proteins**
  - Retinoids as antioxidants may be **consumed by oxidative stress** induced by xenobiotics
  - Interference during **binding to RAR/RXR**
- **Effects**
  - **Decreased retinoid levels in organisms**
    - Downregulation of growth factors
    - Xerophthalmia, night blindness
    - Embryotoxicity, developmental abnormalities
  - **Increased ATRA concentration**
    - teratogenic effects



# Disruption of retinoid signalling by xenobiotics

- **Polluted areas**
  - **mostly decrease of retinoid levels**
    - Documented in aquatic birds, mammals and fish
- **Disruption of retinoid transport: PCBs**
- **Effects on retinoid receptors:**
  - RAR, RXR binding and/or transactivation
    - pesticides (chlordane, dieldrin, methoprene, tributyltin...)
    - Effect on ATRA mediated response – TCDD, PAHs
- **Disruption of retinoid metabolism:**
  - **PCDD/Fs**, PAHs, PCBs, pesticides
  - changes of serum concentrations of retinol and RA
  - mobilization of hepatic storage forms






Figure 1. General molecular structure of polychlorinated dibenzo-p-dioxin (PCDD) and dibenzofurans (PCDF)

# AhR (Arylhydrocarbon receptor)

AhR structure

*Derison et al., Chem Ed. Interact. 141: 3*




2,3,7,8-TCDD  
(dioxin) bound to AhR



# AhR

- Ligand-activated transcription factor
  - Similar to all NRs
- AhR has effects on many different genes
- important mediator of toxicity of POPs – primary target of **planar aromatic substances**
  - regulator of xenobiotic metabolism and activation of promutagens
- Crossactivation/crosstalk with other NRs
- **Strongest known ligand - TCDD**
  - (not endogeneous !)



## AhR regulated genes

- Many genes contain **xenobiotic response elements (XRE)** or dioxin responsive elements (DRE) in their promoter region:
  - phase I enzymes - CYP 1A1, CYP 1A2, CYP 1B1
  - phase II enzymes - UDP-glucuronosyltransferase, GST-Ya, NADP(H):oxidoreductase;
    - **Detoxification upon toxicant exposure**  
... also with possible toxic consequences (oxidative stress, activation of promutagens accelerated clearance of hormones ...)
  - **other genes** - regulation of cell cycle and apoptosis
    - Bax (**apoptosis control**), p27Kip1, Jun B (**MAP-kinase**), TGF-b (**tumor growth factor**)
      - **Various adverse toxic effects**


# Physiological role of AhR

- Physiological role for AhR still not known (?)
  - Most likely – “protection” against toxicants → induction of detoxification
- Many adverse effects documented in **AhR-deficient** mice
  - significant growth retardation;
  - defective development of liver and immune system;
  - retinoid accumulation in liver;
  - abnormal kidney and hepatic vascular structures.
  - resistant to BaP-induced carcinogenesis and TCDD-induced teratogenesis;
  - no inducible expression of CYP 1A1 and 2.

→ this implies presence of **natural endogeneous ligand(s)**  
(not only exogeneous toxicants can bind AhR)

# What is the natural (endogenous) physiological ligand of AhR ?


Potential candidate: 6-formylindolo[3,2-b]carbazole (FICZ)




# Classical and “non-classical” AhR ligands

Classical = planar structures → direct binding to AhR


## “Classical” AhR Ligands and CYP1A1 Inducers




2,3,7,8-Tetrachlorodibenzo-p-dioxin




3,4,3',4',5-Pentachlorobiphenyl




2,3,7,8-Tetrachlorodibenzofuran



3-Methylcholanthrene



Benzo(a)pyrene



β-Naphthoflavone

*Denison & Nagy, Annu. Rev. Pharmacol. Toxicol. 43:309*







# Biological responses to TCDD





Figure 1 Biological responses to TCDD. A wide variety of cellular processes have been shown to be affected by TCDD.

# Toxic equivalency factors (TEF)/TEQ concept

- Toxicity of compounds with similar toxicological properties as TCDD (activating AhR) may be evaluated by TEF/TEQ concept
  - TEF = Toxic Equivalency Factor (“characteristic” of the Chemical)
  - TEQ = Toxic Equivalent (sum of TEFs x concentrations)
- **TEFs are consensus values based on REPs (relative potencies) across multiple species and/or endpoints.**
  - TEFs are based upon a number of endpoints, from chronic in vivo toxicity to in vitro toxicity with the former having the greatest importance in determining overall TEF.
- **TEQs provide a simple**, single number that is indicative of **overall toxicity of a sample** (water, sediment, food) containing a mixture of dioxins and dioxin-like compounds.
- The total potency of a mixture can be expressed in TCDD TEQ concentration
  - i.e. TEQ = concentration corresponding to the effect that would be induced by TCDD

$$\text{TEQ} = \Sigma\{\text{compound}_1 \times \text{TEF}_1 + \dots$$
$$+ \text{compound}_n \times \text{TEF}_n\}$$



# Toxic equivalency factors for PCDDs, PCDFs and PCBs:

**Table 4.** Toxic Equivalent Factors established by the WHO (WHO-TEFs) for dioxins and dioxin-like PCBs [4]

| PCDD Congener   | WHO-TEF | PCDF Congener   | WHO-TEF | PCB Congener      | WHO-TEF |
|-----------------|---------|-----------------|---------|-------------------|---------|
| 2,3,7,8-TCDD    | 1       | 2,3,7,8-TCDF    | 0.1     | <i>Non-ortho</i>  |         |
| 12,3,7,8-PeCDD  | 1       | 12,3,7,8-PeCDF  | 0.05    | PCB#81            | 0.0005  |
| 123478-HxCDD    | 0.1     | 23478-PeCDF     | 0.5     | PCB#77            | 0.0005  |
| 123678-HxCDD    | 0.1     | 123478-HxCDF    | 0.01    | PCB#126           | 0.1     |
| 12,3,7,89-HxCDD | 0.1     | 123678-HxCDF    | 0.1     | PCB#169           | 0.01    |
| 1234678-HpCDD   | 0.01    | 234678-HxCDF    | 0.1     | <i>Mono-ortho</i> |         |
| OCDD            | 0.0001  | 12,3,7,89-HxCDF | 0.1     | PCB#105           | 0.0001  |
|                 |         | 1234678-HpCDF   | 0.01    | PCB#114           | 0.0005  |
|                 |         | 1234789-HpCDF   | 0.01    | PCB#118           | 0.0001  |
|                 |         | OCDF            | 0.0001  | PCB#123           | 0.0001  |
|                 |         |                 |         | PCB#156           | 0.0005  |
|                 |         |                 |         | PCB#157           | 0.0005  |
|                 |         |                 |         | PCB#167           | 0.00001 |
|                 |         |                 |         | PCB#189           | 0.0001  |

*Eljarrat & Barceló, Trends Anal. Chem.22: 655*

Final concentration is expressed as „Equivalents of TCDD“  
(e.g. ng TEQ / kg = ng TCDD / kg)




# Biomarkers/bioanalytical methods for AhR toxicity

- In vivo studies
  - liver enlargement, reduction of thymus weight, wasting syndrome, reproductive and developmental disorders
- In vivo biomarkers
  - **EROD** activity, CYP 1A1 and 1B1 expression (discussed in biomarker section)
- in vitro assessment of chemical potencies
  - EROD (ethoxyresorufin-O-deethylase activity) in cell cultures;
  - **CALUX/CAFLUX assays** (luciferase expression – reporter gene assays)
  - GRAB assay (AhR-DNA binding)
  - yeast bioassay;
  - immunoassays;
  - detection of CYP1A mRNA (qPCR) or AhR protein (western blotting)



# In vitro CALUX/CAFLUX assays

CALUX – Chemical Assisted Luciferase Expression  
DR-CALUX (Dioxin Responsive CALUX)  
(i.e. Luciferase Reporter Gene Assay with H4IIE.luc cells)



Adapted from Blankenship (1994)



# DETECTION of EROD activity - example

140

*M. Till et al. / Chemico-Biological Interactions 117 (1999) 135–150*





Fig. 2. Time course of induction of CYP1A1-catalyzed 7-ethoxyresorufin *O*-deethylase (EROD) activity in primary cultures of rat hepatocytes, after addition of  $1.7 \times 10^{-5}$  M benzo[*a*]pyrene (-▼-),  $1.9 \times 10^{-6}$  M benzo[*k*]fluoranthene (-▲-) or  $9.4 \times 10^{-5}$  M acenaphthylene (-○-). EROD activity was determined in cell homogenates. The data represent means  $\pm$  S.D. from four independent experiments.



# Comparing toxicity of compounds → Application in Risk Assessment

- Quantification of effects ( $EC_{50}$ )
- Comparison with the effect of reference toxicant (2,3,7,8-TCDD)
  - → relative potencies (REPs) to TCDD  
(= in vitro "Toxic Equivalency Factors" ~ TEFs)




TCDD:  $IC_{50}$   
PAH:  $IEC_{50}$

Relative Potency (REP)  
= Induction Equivalency Factor  
 $IEF = IC_{50} / IEC_{50}$

REP interpretation: How many times is the compound "weaker" inducer than TCDD ?

# Example - relative potencies of PAHs (two exposure periods)

*M. Machala et al. / Mutation Research 497 (2001) 49–62*



—●— TCDD - 6h

—●— B[a]P - 6h

—▲— B[k]F - 6h

—■— B[ghi]Pe - 6h

---◇--- TCDD - 24h

---○--- B[a]P - 24h

---△--- B[k]F - 24h

---□--- B[ghi]Pe - 24h





Table 2  
IEFs of PAHs relative to TCDD or B[a]P derived from EC50 or EC25 values in 24 and 6h exposure assays

| Derived from | IEF <sub>TCDD(24h)</sub> |         | IEF <sub>TCDD(6h)</sub> |         | IEF <sub>B[a]P(6h)</sub> |         |
|--------------|--------------------------|---------|-------------------------|---------|--------------------------|---------|
|              | EC50                     | EC25    | EC50                    | EC25    | EC50                     | EC25    |
| Flu          | ni <sup>a</sup>          | ni      | ni                      | ni      | ni                       | ni      |
| Ant          | ni                       | ni      | ni                      | ni      | ni                       | ni      |
| Fla          | 2.27E-8                  | 9.31E-7 | 9.84E-5                 | 1.11E-4 | 1.05E-2                  | 5.59E-3 |
| Py           | 1.78E-6                  | 3.38E-6 | 2.59E-5                 | 4.45E-5 | 7.57E-3                  | 6.21E-3 |
| B[a]A        | 7.04E-6                  | 9.60E-6 | 7.64E-7                 | 2.40E-6 | 0.39                     | 0.50    |
| Chry         | 1.01E-4                  | 1.07E-4 | 1.41E-2                 | 3.26E-2 | 3.25                     | 2.04    |
| B[b]F        | 3.35E-5                  | 4.82E-5 | 4.90E-2                 | 2.32E-1 | 8.83                     | 12.81   |
| B[k]F        | 1.64E-3                  | 2.94E-3 | 0.28                    | 0.57    | 67.76                    | 36.33   |
| B[a]P        | 9.01E-5                  | 1.99E-4 | 1.11E-2                 | 2.02E-2 | 1.0                      | 1.0     |
| DB[ah]A      | 1.17E-3                  | 1.52E-3 | 0.06                    | 0.20    | 11.46                    | 11.72   |
| I[123-cd]P   | 2.96E-4                  | 5.01E-4 | 0.86                    | 1.24    | 44.20                    | 29.70   |
| B[ghi]Pe     | ni                       | ni      | 2.27E-5                 | 4.68E-5 | 5.47E-3                  | 2.99E-3 |
| DB[al]P      | 4.90E-6                  | 1.13E-6 | 2.52E-5                 | 3.26E-5 | 2.36E-2                  | 1.88E-2 |
| NPyr         | 2.05E-4                  | 3.83E-4 | 5.80E-3                 | 1.31E-2 | 1.10                     | 0.88    |
| CPP          | 2.48E-7                  | 6.53E-7 | 6.20E-6                 | 1.72E-5 | 4.23E-3                  | 3.38E-3 |
| B[a]Pe       | 6.19E-6                  | 6.28E-6 | 2.27E-4                 | 3.05E-4 | 3.37E-2                  | 1.68E-2 |
| DB[ae]F      | 9.30E-6                  | 1.18E-5 | 2.75E-5                 | 1.33E-4 | 1.74E-3                  | 6.74E-3 |
| DB[ai]P      | 1.65E-4                  | 4.41E-4 | 4.29E-2                 | 3.82E-2 | 2.59                     | 1.75    |
| DB[ae]P      | 1.80E-5                  | 3.90E-5 | 1.08E-3                 | 3.90E-3 | 0.49                     | 0.13    |
| DB[ah]P      | 7.14E-5                  | 3.70E-4 | 2.65E-2                 | 5.43E-2 | 2.80                     | 2.68    |
| DB[ak]F      | 1.23E-3                  | 1.37E-3 | 1.55E-2                 | 2.02E-2 | 2.69                     | 1.65    |
| 5-MeChry     | 9.48E-5                  | 1.59E-4 | 4.05E-2                 | 5.08E-2 | 3.07                     | 2.46    |
| DB[aj]A      | 3.70E-4                  | 5.21E-4 | 3.07E-2                 | 4.04E-2 | 2.16                     | 2.16    |
| B[j]F        | 3.68E-4                  | 7.40E-4 | 4.05E-2                 | 6.33E-2 | 2.25                     | 2.51    |
| B[c]Phe      | 4.49E-7                  | 1.07E-6 | 6.21E-5                 | 7.51E-5 | 4.64E-3                  | 3.76E-3 |
| B[e]P        | 5.15E-7                  | 6.30E-7 | 3.71E-5                 | 8.17E-5 | 2.27E-3                  | 2.86E-3 |
| DMBA         | 5.41E-6                  | 1.30E-5 | 4.71E-2                 | 3.98E-2 | 0.46                     | 0.9     |
| 1-MePyr      | 2.07E-6                  | 2.82E-6 | 4.80E-5                 | 7.20E-5 | 8.54E-3                  | 6.33E-3 |
| DB[ac]A      | 1.92E-4                  | 4.23E-4 | 3.53E-2                 | 7.80E-2 | 1.75                     | 2.78    |
| Pic          | 4.11E-5                  | 5.54E-5 | 1.90E-3                 | 5.20E-3 | 0.12                     | 0.25    |

<sup>a</sup> ni, no induction observed.

# Summary – Nuclear receptors

- Important physiological functions,
- Important roles in pathologies and chemical toxicity (**ENDOCRINE DISRUPTION**)
- NRs with well studied roles in toxicity: **ER and AhR**
  - Other NRs (AR, RAR/RXR, ThR) – important but less explored
- All NRs share similar structure and mechanisms of action
  - Act as direct **transcription factors** on DNA
- Natural ligands of NRs are small lipophilic hormones
  - steroids, thyroids, retinoids
  - Various regulatory functions
  - Role in toxicity: NR interact with **structurally similar xenobiotics**
- **Various mechanisms beyond the toxicity**
  - Adverse are both STIMULATIONS and INHIBITIONS directly at the receptor site (e.g. “anti-androgenicity”)
  - Additional mechanisms – transport of hormones in blood (Thyroids), metabolism (Thyroids) clearance (Retinoids), heterodimerization and “crosstalk”
- Other key information to remember
  - **REPORTER GENE ASSAYS** (principle, use, what is CALUX?)
  - Characterization of chemical “toxic potentials”
    - General concept of “**REPs**” (valid for activation of all NRs)
    - Specifically for AhR - concept of **TEFs / TEQs**